Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2001

View Archived Issues

Current enrollment accelerating in Emisphere's phase III oral heparin program

Tanox opens enrollment for phase I trial of TNX-355 for HIV

GC-C agonists inhibit colon cancer cell proliferation

Texas Biotechnology announces approval of argatroban in Canada

Early c-Fos induction appears to have neuroprotective role in cerebral ischemia

Phase I trial of oral gluconeogenesis inhibitors for diabetes mellitus set to begin

Long-terms effects of Ac-SDKP assessed in rat model of renovascular hypertension

FDA approves DuPont Pharmaceutical's ultrasound contrast agent Definity

Abbott Laboratories submits NDA for Synthroid ahead of schedule

Novel leukemia drug receives positive opinion from CPMP

Polydex reports latest advancements for development of Usherdex for lung disorders

Letrozole may increase adult height in boys with delayed puberty

ViroPharma files NDA for pleconaril for the treatment of viral respiratory infection in adults

Phase II trial of ABX-EGF for non-small cell lung cancer initiated

Corixa receives milestone payment for lung cancer vaccine

Patient enrollment completed in Xcytrin phase II clinical trial for glioblastoma multiforme

Memantine to be evaluated in the treatment of diabetic neuropathy

Use of beta-adrenoceptor antagonists for treating outer retina disorders described

Ono Pharmaceutical presents a new series of cysteine protease inhibitors

VLA-4 integrin antagonists presented by Novartis

Novel adamantane derivatives and their use described by AstraZeneca

Compounds useful for the treatment of chronic inflammatory diseases patented by F. Hoffmann-La Roche

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...